1. Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents
- Author
-
Jia-Horng Kao, Tai-Chung Tseng, Hung-Chih Yang, Tung-Hung Su, Pin-Nan Cheng, Pei-Jer Chen, Chun-Jen Liu, Shang-Chin Huang, and Chen-Hua Liu
- Subjects
Hepatitis B virus ,medicine.medical_specialty ,Chemokine ,Hepacivirus ,CCL2 ,Antiviral Agents ,Gastroenterology ,Internal medicine ,medicine ,Humans ,Interferon gamma ,biology ,Coinfection ,Tumor Necrosis Factor-alpha ,business.industry ,virus diseases ,General Medicine ,Hepatitis C, Chronic ,Hepatitis B ,medicine.disease ,Hepatitis C ,Normal limit ,digestive system diseases ,Serum cytokine ,biology.protein ,Cytokines ,Virus Activation ,Tumor necrosis factor alpha ,Chemokines ,business ,Direct acting ,medicine.drug - Abstract
BACKGROUND/PURPOSE Direct-acting antiviral agents (DAAs) have revolutionized the paradigm for HCV treatment. However, patients with HBV and HCV co-infection receiving DAAs are at significant risk of HBV reactivation, with limited literature addressing the roles of serum chemokines/chemokines. We aimed to explore the profiles and predictive value of serum cytokines/chemokines regarding HBV reactivation in this clinical setting. METHODS From 2017 to 2019, 25 patients with HBV and HCV co-infection scheduled for DAA therapy were prospectively enrolled. At enrolment and after DAA treatment, serial serum cytokine/chemokine levels were examined. The baseline and dynamic levels were compared between those with versus without HBV virologic (defined by an increase of serum HBV DNA to >10 times) and clinical reactivation (defined by > 1.5-fold elevated ALT level than nadir and >100 U/L; or > 2-fold increase from nadir and greater than the upper normal limit, in addition to virologic reactivation). RESULTS There were 20 patients (80%) experiencing HBV virologic reactivation and 6 patients (24%) experiencing clinical reactivation. Patients with clinical reactivation had higher pre-treatment TNF-alpha (27.93 versus 18.85 pg/mL, P = 0.015), lower week-4 IFN-gamma (1.07 versus 8.74 pg/mL, P = 0.020) levels and significant declines of CCL2 and TNF-alpha (P
- Published
- 2022